Provided by Tiger Fintech (Singapore) Pte. Ltd.

Gilead Sciences

109.06
-3.0300-2.70%
Post-market: 108.59-0.4671-0.43%19:58 EDT
Volume:4.94M
Turnover:540.32M
Market Cap:135.66B
PE:23.05
High:111.49
Open:110.94
Low:108.73
Close:112.09
Loading ...

Gilead Sciences Inc. Stock Slides 4.3%, Underperforms Competitors

Dow Jones
·
12 Jul

BUZZ - Nasdaq top and bottom performing stocks at about 11:01 a.m. EDT on 2025-07-11

Reuters
·
11 Jul

BRIEF-Briacell’S Bria-Imt™ Demonstrates Survival Advantage Over Trodelvy® And Control Group In Metastatic Breast Cancer

Reuters
·
11 Jul

Briacell’s Bria-Imt™ Demonstrates Survival Advantage Over Trodelvy® and Control Group in Metastatic Breast Cancer

THOMSON REUTERS
·
11 Jul

Morgan Stanley Keeps Their Buy Rating on Gilead Sciences (GILD)

TIPRANKS
·
10 Jul

Gilead Sciences Inc. Stock Outperforms Competitors On Strong Trading Day

Dow Jones
·
10 Jul

Gilead Sciences Inc. Advances HIV Prevention Efforts with European Medicines Agency Validation of Lenacapavir Application

Reuters
·
09 Jul

BRIEF-Gilead Finalizes Agreement With Global Fund To Accelerate Access To Lenacapavir

Reuters
·
09 Jul

Gilead Finalizes Agreement With the Global Fund to Accelerate Access to Twice-Yearly Lenacapavir for Hiv Prevention for up to Two Million People in Primarily Low- and Lower-Middle-Income Countries

THOMSON REUTERS
·
09 Jul

Gilead Sciences: to Provide Lenacapavir to 2 Mln People Over 3 Years in Countries Supported by Global Fund, at No Profit to Gilead

THOMSON REUTERS
·
09 Jul

Gilead Sciences: Agreement With Global Fund to Accelerate Access to Lenacapavir for Hiv Prevention in Low-Income Countries

THOMSON REUTERS
·
09 Jul

Positive Outlook for Gilead Sciences Driven by Yeztugo’s Market Potential and FDA Approval

TIPRANKS
·
09 Jul

RBC Capital Sticks to Their Hold Rating for Gilead Sciences (GILD)

TIPRANKS
·
08 Jul

RBC Lifts Price Target on Gilead Sciences to $96 From $95, Keeps Sector Perform Rating

MT Newswires Live
·
07 Jul

Gilead Sciences’ Ongoing Study on TAF for Pediatric Hepatitis B: Market Implications

TIPRANKS
·
05 Jul

Gilead Sciences’ Promising Phase II Study on Sacituzumab Govitecan for Solid Tumors

TIPRANKS
·
03 Jul

Gilead Sciences Inc. CEO Daniel O'Day Reports Disposal of Common Shares

Reuters
·
02 Jul

Wells Fargo Sticks to Their Buy Rating for Gilead Sciences (GILD)

TIPRANKS
·
29 Jun

Analysts Are Bullish on These Healthcare Stocks: Arcturus Therapeutics (ARCT), Gilead Sciences (GILD)

TIPRANKS
·
29 Jun

BUZZ - Nasdaq top and bottom performing stocks at about 02:45 p.m. EDT on 2025-06-27

Reuters
·
28 Jun